

FINTEPLA REMS Prescriber Knowledge Assessment

FINTEPLA is available only through the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS).

Instructions

1. Review the *FINTEPLA Prescribing Information, Prescriber Training, and REMS Program Overview*
2. Successfully complete and submit this *Prescriber Knowledge Assessment* at www.FinteplaREMS.com or fax to 1-833-568-6198 or mail to 1710 N Shelby Oaks Dr, Ste 3, Memphis, TN 38134
3. Complete all required fields on this form to avoid a delay in the enrollment process

PRESCRIBER INFORMATION

* indicates required field.

First Name*:	Phone*:
Last Name*:	Email*:
National Provider Identifier (NPI)*:	

PRESCRIBER ASSESSMENT

Answer the following questions by selecting the single best answer. You must answer ALL questions correctly to become certified in the REMS.

Question 1	The goal of the REMS is to mitigate the risk of valvular heart disease and pulmonary arterial hypertension.	True	False
Question 2	In order to receive FINTEPLA, patients must enroll in the REMS.	True	False
Question 3	FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.	True	False
Question 4	The signs and symptoms of valvular heart disease and pulmonary arterial hypertension may include:	Shortness of breath Fatigue Dizziness or fainting Swelling of ankles and feet Rapid heartbeat All of the above	
Question 5	A patient must obtain an echocardiogram at baseline (treatment initiation), every 6 months during treatment, and once 3 to 6 months after treatment discontinuation.	True	False
Question 6	I don't need to document the results of the echocardiogram for each patient on the <i>Patient Status Form</i> in order to prescribe FINTEPLA.	True	False
Question 7	I may be contacted by the REMS program for further information regarding any reports of valvular heart disease and pulmonary arterial hypertension.	True	False
Question 8	Only pharmacies certified in the REMS may dispense FINTEPLA to patients.	True	False
Question 9	An echocardiogram can identify evidence of valvular heart disease or pulmonary arterial hypertension prior to a patient becoming symptomatic.	True	False

If you have any questions or need additional information, please visit www.FinteplaREMS.com or call 1-877-964-3649, Monday through Friday, between 7 AM and 7 PM Central Time.



FINTEPLA® is a registered trademark of the UCB Group of Companies.
 ©2023 UCB, Inc., Smyrna, GA 30080. All rights reserved.
 US-P-FA-DS-2300070

Phone: 1-877-964-3649 | www.FinteplaREMS.com | Fax: 1-833-568-6198

Fintepla
 (fenfluramine)
 2.2 mg/mL oral solution